The National Organization for Rare Disorders (NORD), along with The ALS Association, Cystic Fibrosis Foundation and Muscular Dystrophy Association, is pleased to host a special webinar with leaders from the US Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) to discuss the COVID-19 vaccines with the rare disease community. FDA recently granted Emergency Use Authorization (EUA) for the Pfizer and Moderna COVID-19 vaccines. Questions that will be addressed include: What do the EUAs of these vaccines mean for the rare disease community? When might other vaccines receive an EUA? Are there special considerations for the rare disease community with respect to the COVID-19 vaccines? What role does CDC play with respect to vaccines? Additional questions from members of the rare community will be collected during the registration period and addressed in the live webinar. This webinar is intended for patients, caregivers, advocates and the general public. For those unable to join live, this webinar will be recorded and a viewing link sent to all registrants for on-demand viewing. Date: January 15, 2021 Time: 2:00 – 2:45pm ET REGISTER NOW Speakers Dr. Stephen Hahn, Commissioner of Food and Drugs, FDA Dr. Peter Marks, Director, Center for Biologics Evaluation and Research, FDA Dr. Amanda Cohn, Chief Medical Officer, Office of Vaccine Policy, Preparedness and Global Health, Office of the Director, NCIRD, CDC Opening Remarks Peter L. Saltonstall, President and Chief Executive Officer, NORD Moderator Rachel Sher, JD, MPH, Vice President, Policy and Regulatory Affairs, NORD Supporting Organizations